Audi scraps its logo in bold new EV brand
After months of rumous, Audi has unveiled a new EV range in China, sporting, instead of the rings (arguably one of the best ...
Monthly Prescribing Reference10d
Drugs in the Pipeline
IGA score of cleared (0) or minimal disease (1) was achieved by a significantly greater proportion of those in the guselkumab vs placebo group, 74.2% vs 12.4%, respectively. Arexvy is currently ...
Seeking Alpha16d
GSK Q3 Earnings Preview: Shingrix And Arexvy Make The Stock A 'Strong Buy'
GSK's major growth drivers, Shingrix and Arexvy, along with recent legal progress, make its current undervaluation unjustified, leading to a "Strong Buy" rating. The company’s diversified ...
Vietnam Investment Reviev16d
Partnership between LianLian Global and WeChat Pay transforms tourist experience at Grand Palace
BANGKOK , Oct. 26, 2024 /PRNewswire/ -- LianLian Global has partnered with WeChat Pay to streamline the ticket purchasing process for visitors to Bangkok's Grand Palace. The collaboration leverages ...
Pharmabiz17d
New data for Arexvy, GSK’s RSV vaccine, show potential to help protect a broader group of adults at increased risk for RSV disease
GSK plc announced new preliminary data for Arexvy (respiratory syncytial virus vaccine, recombinant adjuvanted) in adults aged 18-49 at increased risk for RSV-LRTD due to certain underlying medical ...
Business Insider17d
Graham Parry Recommends Sell Rating for GlaxoSmithKline Due to Concerns Over Arexvy Vaccine Efficacy and Safety
Graham Parry has given his Sell rating due to a combination of factors affecting GlaxoSmithKline’s Arexvy vaccine. The challenges highlighted include the limited effectiveness of a single shot ...
MM&M17d
Rx Rundown: Opella, Samsung Biologics, Dimension and more
Pfizer axed 80 Kansas employees in the second round of cuts this month ... GSK announced a single dose of Arexvy elicited robust immune response with acceptable safety profile in adults aged 18-49 at ...
The Pharma Letter17d
New data for GSK’s Arexvy RSV vaccine
US pharma major GSK (LSE: GSK) yesterday announced new preliminary data for Arexvy (respiratory syncytial virus vaccine, recombinant adjuvanted) in adults aged 18-49 at increased risk for RSV-LRTD due ...
BioSpace17d
CDC Reaffirm RSV Vaccination Guidelines, Declines Expanding Coverage to Younger Adults
GSK’s Arexvy—which became the industry’s first FDA-approved RSV shot in May 2023—was greenlit for use in adults aged 50 to 59 in June 2024. On Thursday, GSK unveiled Phase IIIb data showing that a ...
Investing17d
GSK reports promising Arexvy vaccine data for younger adults
GSK plc (LSE/NYSE: LON:GSK), the global healthcare company, today announced preliminary data from ongoing clinical trials that suggest its respiratory syncytial virus (RSV) vaccine, Arexvy, may be ...
Investing17d
GSK reports promising Arexvy vaccine data for younger adults
GSK plc (LSE/NYSE: GSK), the global healthcare company, today announced preliminary data from ongoing clinical trials that suggest its respiratory syncytial virus (RSV) vaccine, Arexvy ...
Benzinga.com17d
Just After Pfizer's RSV Vaccine Approval For Younger Adults, GSK Layouts Encouraging Preliminary Data Showing Potential For Use In Larger Population
GSK's Arexvy shows strong immune response in adults aged 18-49 at risk for RSV-related respiratory disease. Over 21 million U.S. adults aged 18-49 may be at risk for RSV due to underlying conditions.